Stallergenes' pollen therapy positive in US Phase III study
This article was originally published in Scrip
Executive Summary
Stallergenes' sublingual allergy desensitisation product Oralair has met the primary endpoint of the reduction of allergy symptoms in its first US Phase III study. The French biotech company plans to file the drug with the US FDA early next year.